The diluted loss per share for the three months ended June 30, 2024 was determined excluding the effect of 3.82 million dilutive shares as the impact of such shares would have been antidilutive due to ...
Hosted on MSN
Pfizer raises 2025 EPS guidance to $2.90–$3.10 while targeting margin expansion through $7.7B cost savings by 2027
Albert Bourla, Chairman and CEO, highlighted progress in R&D, expansion of the commercial portfolio, and improved margins, stating the company is “raising our adjusted diluted EPS guidance for full ...
Globus Medical raises 2026 EPS guidance to $4.40-$4.50 with margin gains following record Q4 results
Q4 2025 earnings call recap: revenue/EPS beats, margin expansion, Nevro integration, and raised 2026 guidance—read key takeaways.
CFO Ann Kelly reported, “We were pleased to report full year 2025 diluted EPS of $2.92 and adjusted diluted EPS of $2.99. This compares to full year 2024 diluted EPS of $2.87 and adjusted diluted EPS ...
Information reconciling certain forward-looking GAAP measures to non-GAAP measures related to FY 2025 guidance, including organic net sales growth, adjusted operating margin and adjusted free cash ...
TYSONS CORNER, Va.--(BUSINESS WIRE)--Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR) (“Strategy” or the “Company”), the largest corporate holder of bitcoin ...
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...
FY25 consensus $3.88. The company is reaffirming its previously announced fiscal year 2025 guidance of: Net Sales growth of 4% to 6%; Adjusted EBITDA growth of 9.5% to 12%; Adjusted Diluted EPS growth ...
Information reconciling certain forward-looking GAAP measures to non-GAAP measures related to FY 2026 guidance, including organic net sales growth, adjusted operating margin and adjusted free cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results